A carregar...
Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more MR-specific. From a marginal role as a potassium-sparing diuretic, spironolactone...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3796852/ https://ncbi.nlm.nih.gov/pubmed/24133375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IBPC.S13783 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|